Gsk Share Discussion Threads

[dr biotech] 24/5/2018 20:44

GSK at Barnard castle was the first pharma company I visited for work, 1996. Never been back there but been often to ware/Harlow/Stevenage and Worthing. They have closed Harlow and parts of Worthing too, wouldn’t surprise me if they consolidated on just two or three..

[grahamite2] 24/5/2018 15:39

I sold at £16 and bought back at £15 and was feeling pretty pleased with myself - for a matter of days. Good to see it getting a bit healthier.

[romeike] 24/5/2018 13:58

@jrpoenixw2 - thanks, aware of that, my post was intended as seeing this as a positive for GSK. I agree on rate rise - BoE will only raise if it has no other choice due to inflation.

[jrphoenixw2] 24/5/2018 11:46

@Romeike. Sterling weakness boosts converted foreign earnings for GSK and other MNCs. That's a major reason why the FTSE is up nudging records this year: 'Despite BREXIT'.

re: Interest rates. With the recent path of easing inflation, + BREXIT uncertainty in the present/future, I reckon a BoE hike will continue to be progressively pushed back, and perhaps by late summer they might not be [credibly] threatening any until 2019.

[alphorn] 24/5/2018 09:36

Barnard Castle - NEWS that up to 200 jobs are at risk at one of the region's largest employers has been described as a "devastating blow" to the community.
GlaxoSmithKline (GSK) confirmed it is reviewing roles at its Barnard Castle site as part of operational cuts over a three-year period.

[tradermichael] 24/5/2018 09:33

MUMBAI: A whopping 40% tax burden might hobble the sale of British pharma giant GlaxoSmithKline̵7;s (GSK) Indian consumer products division and to tip toe around the hurdle it has sought potential buyers open to a merger and share swap as part of the deal, two people in the know told ET.

GSK fears a 40% tax liability in India would amount to at least $ 1.6 billion. So, instead of selling the Horlicks brand to the potential buyer, the company has now decided to sell Indian entity entirely ..

Read more at:
//economictimes.indiatimes.com/articleshow/64297665.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst

[romeike] 23/5/2018 12:58

Not looking good for sterling, quite possibly the UK is already in recession - BOE says interest rate rise in Aug after backtracking on the much vaunted April rise.

[jrphoenixw2] 22/5/2018 18:46

Yes, agreed Tim3. If you take prices from some channels, esp. those who ignore the official after-market/auction then you can end up with seriously dodgy quotes and ranges. That's why esp. for *closing data/px's*, I now go to the LSE site. Yep it's a bummer that I have to wait for their 'Delayed quote' to work through, but at least I know when it comes it'll be accurate.

[tim 3] 22/5/2018 18:19

Some providers like money a m sometimes seem to include pre and post market silly prices in the days range.

[jrphoenixw2] 22/5/2018 18:10

@Jadet, if in doubt I 'go to source', in this case the LSE which records the high as 1516p
hxxp://www.londonstockexchange.com/exchange/prices-and-markets/stocks/summary/company-summary/GB0009252882GBGBXSET1.html

[ny boy] 22/5/2018 17:29

No not true

[ashbox] 22/5/2018 15:20

£15.148 seems to be ADVFN day high....

[jadeticl3] 22/5/2018 15:12

Just come home. Looked at share price. It says the day’s high is £15.28. Can this be true?

[ny boy] 22/5/2018 15:05

Possibly but mainly investors have been buying because they seem to have been too cheap and the quartely divi is attractive as well as capital growth on the recovery

[tradermichael] 22/5/2018 14:02

Helped by the £ dropping against the USD

[ny boy] 22/5/2018 10:42

Hello 1540p resistance, not far off..through that and not much until main resistance at 1690p

[tradermichael] 22/5/2018 07:15

GlaxoSmithKline PLC (GSK.LN) said that its majority-owned joint venture ViiV Healthcare has been granted marketing authorization by the European Commission for its HIV treatment Juluca.
Juluca has been approved for HIV-1 in adults who are virologically suppressed and who have been on an antiretroviral treatment regimen for at least six months, the GlaxoSmithKline said.

[stewart64] 21/5/2018 17:21

Well the Bid price remained at £15.00, if not the share price.

[ny boy] 21/5/2018 17:12

Nice close, looks like 1540p is in range unless US equities start selling off, sooner or later high oil prices are going to suffocate many stocks.

Sell in May and go away, maybe this year, who knows, it could be a time for market participants to take some chips off the table but I doubt this stock will suffer much, as it’s a good defensive play and starting to make an upward move off a low base.

[stewart64] 21/5/2018 15:52

Be nice if GSK could pass and hold £15 at close. Probably put the mockers on it now.

[nico9] 21/5/2018 15:50

getting close to breaking that £15 barrier. Then onward back to £17 with any luck

[fangorn2] 21/5/2018 11:21

Two bits of interesting news...

U.S. and European regulators said they were assessing evidence that GlaxoSmithKline's HIV drug dolutegravir might be linked to serious birth defects, casting a shadow over a medicine that has been a key profit driver in recent years.


Glaxo's Nucala delivers sustained treatment benefit in long-term study

Updated results from a long-term open-label study, COLUMBA, evaluating GlaxoSmithKline's (NYSE:GSK) Nucala (mepolizumab) in patients with severe eosinophilic asthma showed a durable treatment effect. The data were presented at the American Thoracic Society International Conference in San Diego.

Patients receiving Nucala for an average of 3.5 years and a maximum of 4.5 years experienced a 61% decrease in exacerbation rate (1.74 events/year to 0.68 events/year) and improved asthma control. One third of participants experienced no exacerbations.

[tradermichael] 21/5/2018 08:22

craigo121 - filtered